GlassScriptPhysician profile
Danny Blayne Laws
NPI 1306890645
$12,495.86
in general payments reported to CMS, 2019-2025
50 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $1,598 · 2021: $2,159 · 2022: $1,602 · 2023: $2,044 · 2024: $1,873 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,861.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,634.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,537.96 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $1,070.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $855.14 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $844.86 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Corium, LLC | $614.63 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $578.01 | 2019-2025 | Trintellix |
| Noven Therapeutics, LLC | $524.97 | 2023-2025 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $444.02 | 2019-2023 | Belsomra, Steglatro |
| Supernus Pharmaceuticals, INC. | $378.56 | 2021-2025 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.52 | 2019-2025 | Jardiance |
| Tris Pharma INC | $346.57 | 2019-2025 | Dyanavel Xr |
| Pfizer INC. | $281.84 | 2019-2025 | |
| Axsome Therapeutics, INC. | $278.65 | 2022-2025 | Auvelity, Sunosi |
| Amgen INC. | $238.43 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Laws listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.